ZYME

Zymeworks Stock Price

43.78
-1.56 (-3.44%)
Upgrade to Real-Time
Regular Market
43.78
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.56 -3.44% 43.78 14:25:28
Close Price Low Price High Price Open Price Previous Close
43.26 44.54 44.38 45.34
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,479 365,893 $ 43.87 $ 16,051,115 541,948 20.33 - 52.75
Last Trade Time Type Quantity Stock Price Currency
14:25:25 1 $ 43.73 USD

Zymeworks Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.00B 45.63M 45.26M $ 29.54M $ - -3.82 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.33M $ - 0.00% 1.13k 1.00%

more financials information »

Zymeworks News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZYME Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week40.9745.5939.0542.041,126,9062.816.86%
1 Month32.4045.5929.2837.92685,28411.3835.12%
3 Months36.0445.5928.7134.88497,5567.7421.48%
6 Months26.6845.5925.440735.58457,52217.1064.09%
1 Year27.3052.7520.3337.05428,68416.4860.37%
3 Years8.2152.756.9530.20229,74835.57433.25%
5 Years13.5052.756.2529.82206,72330.28224.3%

Zymeworks Description

Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.


Your Recent History
NYSE
ZYME
Zymeworks
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.